Iconovo AB Company Description

Iconovo AB (publ) develops and licenses inhalation medications in Sweden.

The company offers ICOres, a flexible multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone Nasal single-dose dry powder inhaler for nasal use.

It serves generic companies. The company has collaboration agreement with Affilogic, ENA Respiratory Pty Ltd, Lonza, and Stevanato Group, as well as licensing agreements with Kiox Pharma and Monash University.

Iconovo AB (publ) was founded in 2013 and is headquartered in Lund, Sweden.

Iconovo AB (publ)

Country	Sweden
Founded	2013
Industry	Medical Devices
Sector	Healthcare
Employees	25
CEO	Johan Waborg

Contact Details

Address: Ideongatan 3 A-B Lund, 223 70 Sweden
Phone	46 4 62 75 67 77
Website	iconovo.se

Stock Details

Ticker Symbol	ICO
Exchange	Nasdaq Stockholm
Fiscal Year	January - December
Reporting Currency	SEK
ISIN Number	SE0010868943
SIC Code	3841

Key Executives

Name	Position
Johan Waborg	Chief Executive Officer
Dr. Orest Lastow	Co-Founder, Senior Scientific Advisor and Director
Henrik Damkjaer Simonssen M.Sc.	Chief Financial Officer
Dr. Mikael Arinder	Vice President of Operations
Lotta Askerlund	HR Manager
Carl Forslund	Head of Industrial Design
Therese Dahl	Business Controller